Compare EHTH & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHTH | HBIO |
|---|---|---|
| Founded | 1997 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5M | 26.5M |
| IPO Year | 2006 | 2000 |
| Metric | EHTH | HBIO |
|---|---|---|
| Price | $0.73 | $7.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $3.33 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 352.6K | 15.3K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $251,395,000.00 | $116,176,000.00 |
| Revenue This Year | N/A | $4.77 |
| Revenue Next Year | $5.60 | $8.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 45.86 | N/A |
| 52 Week Low | $0.75 | $0.38 |
| 52 Week High | $5.89 | $8.40 |
| Indicator | EHTH | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 23.30 | 59.14 |
| Support Level | N/A | $5.84 |
| Resistance Level | $1.58 | $8.19 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 7.57 | 31.97 |
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is derived from the United States. It also has a presence in China.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.